Henlius and Sandoz Form a Strategic Partnership to Maximize the Worldwide Potential of their Biosimilars Platform

On August 17, 2026, Henlius and Sandoz have launched a strategic association that may include up to 10 proposed biosimilars of monoclonal antibodies and antibody-drug conjugates, consequently extending their current partnership into a wider global platform. Sandoz will have the rights to registration and commercialization outside China, while Henlius will be in charge of development, manufacturing and supply. The first agreement covers biosimilars of cetuximab, evolocumab and belimumab, together with an alternative relating to recombinant human hyaluronidase. 

The development and manufacturing, with proven global market-access expertise, could thus help to speed up the availability of more affordable biologic treatment options in international healthcare infrastructure. The deal may bring Henlius US$100.5 million in the form of upfront payments, milestone payments, and option payments. This contract boosts Sandoz's biosimilar pipeline and gives Henlius access to Sandoz's international commercialization capabilities. Additionally, it shows that there is increasing interest among medical companies in partnerships that combine the strengths of biologics through biosimilar partnerships.

Impact on the Biopharmaceutical Sector

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035. 

According to Precedence Research, as the biopharmaceutical sector inclines towards partnership, it could improve competition and alter global biosimilar supply chains. This partnership has the potential to speed up the international commercialization of biosimilars developed in China by bringing together Henlius's abilities in advancement and manufacturing with Sandoz's experience in global commercialization. For competitors, the agreement shows that there is growing strategic value in acquiring biosimilar assets at an early stage of development, especially in the areas of monoclonal antibodies and antibody-drug conjugates. 

It includes up to 10 assets; the arrangement amounts to a platform-level alliance aligned with a single-product licensing agreement and could thus improve development efficiency and portfolio diversification. It might lead to further cross-border licensing deals involving biopharmaceutical companies from emerging markets as well as well-established global firms.

Impact on the Patient Engagement Solutions Sector

The global patient engagement solutions market size is calculated at USD 26.36 billion in 2025 and is predicted to increase from USD 30.40 billion in 2026 to approximately USD 98.46 billion by 2035, expanding at a CAGR of 14.09% from 2026 to 2035.

According to Precedence Research, the agreement has the potential to benefit medical systems by increasing competition in the well-developed biologic treatments. The first set of assets covers therapeutic frameworks in cancer, cardiovascular disease, and autoimmune disorders, which may lead to greater availability of treatments. The partnership thus constitutes a potentially notable move towards wider access to biologic medicines, even though substantial patient benefits and patient engagement solutions.

If biosimilars are successfully developed, approved, and put on the market, they could offer more treatment options and ensure cost-efficiency for healthcare providers, payers, and patients. Additionally, the real impact will vary depending on regulatory approvals, manufacturing quality, reimbursement policies, physician acceptance, and the success of market launches. 

Impact on the Pharmaceutical Sector

The global pharmaceutical market size is calculated at USD 1.77 trillion in 2025 and is predicted to exceed USD 3.20 trillion by 2035, with a CAGR of 6.10% from 2026 to 2035.

According to Precedence Research, From the point of view of pharmaceutical investment these agreement shows that platform-based biosimilar transactions. Henlius is given financial opportunities tied to milestones and an already existing international route for commercialization. The Sandoz acquires access to a wider range of assets, which could total 10 monoclonal antibodies.

This arrangement can lower the barriers to commercialization and share the development risks between the two partners. It also illustrates the way in which pharmaceutical companies are increasingly making use of strategic licensing in order to strengthen their pipelines. The expansion of portfolios and taking advantage of the opportunities linked to the expirations of biologic patents together with exclusivity periods. The deal may prompt a greater number of cross-country partnerships involving pharmaceutical companies based in China. 

Expert Opinion

In the view of the expert, this joint effort is crucial in a typical biosimilar licensing arrangement and functions as a strategic framework between a Chinese biologic’s developer and a global biosimilar company. This agreement enables Henlius to gain an international route for the commercialization of its development and manufacturing capabilities. Sandoz to strengthen its pipeline and prepare for future opportunities arising from the loss of exclusivity of biological drugs.

This strategy could serve as a useful example of cross-border biosimilar partnerships and might also highlight the increasing role of Chinese biotechnology companies in providing globally competitive biologic medicines and in influencing the next stage of biosimilar market growth. The fact that a number of assets are involved shows a readiness to work together across a wider development portfolio rather than concentrating on individual products. The main challenge will be carrying out the agreement, as the assets will still have to meet the requirements relating to regulatory approval, development, manufacturing and market access.